NICE approves Pfizer's cancer drug Ibrance combined fluorovis group for treatment of patients with localized advanced or metastatic breast cancer

recently, Pfizer announced that the National Institute sequinor (NICE)http://
has approved the acquisition of the targeted anti-cancer drug Ibrance (Aboxin, Palbociclib, pyroxici), a combination of fluoroviris for the treatment of previously endocrine-treated hormone receptor-positive (HR-) and human epidermal growth factor 2 negative (HER2-late-stage) (her2-late-stage) breast cancer patients (CDF)Results from the Phase III ClinicalTrial(http://PALOMA-3 showed that in patients with HR/HER2-breast cancer who progressed during or after receiving endocrine therapy, ibrance and fluorovis group delayed disease progression by 6.6 months (11.2 months vs4.6 months; HR s.497.95%: CI.398-02) compared to the placebo-fluovilous groupby extending progression-free survival (PFS), the ibrance-fluorovis group combination therapy delayed the need for follow-up treatments, including chemotherapy, to make patients better off living in the long-term stability of the diseaseabout Ibrance
Ibrance is a first-of-its-kind oral targeted CDK4/6 inhibitor that selectively inhibits cell cycle protein-dependent kinases 4 and 6 (CDK4/6), restores cell cycle control, and blocks tumor cell proliferationOut-of-control cell cycle is a hallmark of cancer, and CDK4/6 is overactive in many cancers, causing cell proliferation to spiral out of controlCDK4/6 is a key regulatory factor for the cell cycle, which can trigger the transition of the cell cycle from the growth (G1 phase) to the DNA replication period (S1)in estrogen receptor-positive (ER-plus) breast cancer, CDK4/6 is very active and CDK4/6 is a key downstream target for ER signalsPreclinical data show that CDK4/6 and ER signal double inhibition has synergy, and can inhibit the growth of G1 stage ER-breast cancer cellsIn April 2019, Ibrance was approved by the U.SFDA(http://as a cdK4/6 inhibitor in a male patient with combined aromatase inhibitors for HR-HER2-metastatic breast cancerin the United States, Ibrance is used to treat adult patients with HR-HER2-advanced or metastatic breast cancer: (1) a combination of aromatase inhibitors as an initial endocrine therapy for postmenopausal women or men;In China, Ibrance was approved in August 2018 as a combination of aromatase inhibitors as an initial endocrine therapy for the treatment of postmenopausal women with HR-HER2-localized advanced or metastatic breast cancer